Drug Trial Radar · NCT07175233
A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
184
Actual
Start
Oct 28, 2025
Primary completion
Sep 23, 2026
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult patients (18-75 years) with moderate to severe AD suitable for systemic therapy. Approximately 184 subjects with moderate to severe AD are planned to be randomized in a 1: 1: 1: 1 ratio to SIM0278 low dose, SIM0278 medium dose, SIM0278 high dose, or placebo. Subjects were stratified at randomization by baseline disease severity (moderate \[IGA = 3\] VS severe \[IGA = 4\]). The study consisted of 4 phases: screening, double-blind induction, open-label maintenance, and safety follow-up.
Conditions
- Atopic Dermatitis (AD)
Interventions
SIM0278 injectionDrug
SIM0278 injection
PlaceboOther
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 16 (W16).Time frame: At Week 16 (W16)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Affiliated Hangzhou First People's Hospital, School of Medicine , West Lake University
Hangzhou, China
The First Hospital of China Medical University
Shenyang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.